Medica Venture Partners

About

Portfolio

Investment activity

5 portfolio exits on record.

Q&A

What is Medica Venture Partners' primary investment focus?

Medica Venture Partners is a globally operating healthcare and life sciences venture capital fund, investing in medical devices, pharmaceuticals, biotech, and genomics.

Where does Medica Venture Partners primarily invest?

Medica Venture Partners invests in Israel, Europe, and the United States, with an extensive operational base in Israel.

Who is a key founding member of Medica Venture Partners?

Ehud Geller is a Managing Partner and a founder of Medica Venture Partners.

Which portfolio company of Medica Venture Partners went public in September 2020?

PainReform, a company focused on pain treatment drugs, went public on NASDAQ in September 2020, raising $23M.

Which portfolio company was acquired in June 2018?

Expanding Orthopedics, which develops expandable devices for spine surgery, was acquired by CoreLink in June 2018.

What is a notable public exit for Medica Venture Partners in the future?

Regentis Biomaterials, an implantable hydrogel platform for tissue regeneration, is slated for a public offering on NASDAQ in September 2025, having raised $11M in capital.

Which company in Medica Venture Partners' portfolio focuses on dermatological drugs?

Sol-Gel Technologies, which specializes in silica microencapsulation technology for dermatological drugs, is a portfolio company of Medica Venture Partners.

What is the primary sector for Medica Venture Partners' investments and exits?

Medica Venture Partners shows a strong concentration in the Health Tech & Life Sciences sector, with all 7 of its portfolio companies and 5 of its exits being in this area.